🇦🇪 Free peptide education for UAE residents · DHA/DOH-verified clinics
Retatrutide

GLP-1 / Weight

Retatrutide

Licensed physician protocols only

An investigational triple GLP-1/GIP/glucagon receptor agonist that produced some of the largest weight-loss figures yet seen in trials — not yet registered in the UAE.

Also known as: LY3437943 · Triple-G

Reviewed by the Peptide Guide UAE clinical teamLast updated: July 2026Preclinical / limited human evidence
  • Phase 2 average weight loss above 24% at the top dose
  • Triple GLP-1 / GIP / glucagon mechanism
  • Studied improvements in glycaemic and liver-fat markers
RE
Licensed physician protocols only

Retatrutide

GLP-1 / Weight

from

Not commercially available

UAE access

Licensed physician protocols only

Emerging / not yet registered in the UAE. Retatrutide is an investigational medicine (Phase 3 TRIUMPH programme ongoing) and is not approved or available for prescription in the UAE. This page is educational only.

Find a DHA-licensed clinic offering Retatrutide →

Pricing

MonthlyNot commercially available
ConsultationAED 400–900
Full programmeNot commercially available
BloodworkAED 500–1,600

Book this protocol in the UAE

Links open the clinic’s relevant service page. Always confirm availability and pricing directly before booking.

How it works

Retatrutide activates three receptors at once — GLP-1, GIP and glucagon. Alongside the appetite-suppressing and insulin-sensitising effects of GLP-1/GIP agonism, glucagon-receptor activity is thought to raise energy expenditure and support fat metabolism. In Phase 2 trials this triple mechanism produced average weight loss exceeding 24% at the highest dose over 48 weeks.

Not sure if this fits your goals?

2-min match →

Key benefits

Phase 2 average weight loss above 24% at the top dose
Triple GLP-1 / GIP / glucagon mechanism
Studied improvements in glycaemic and liver-fat markers
Once-weekly dosing in trials

Protocol overview

Retatrutide is investigational and has no approved clinical protocol. Trial regimens use once-weekly subcutaneous titration. It is not available for prescription; any information here is educational and any future use must be under a licensed physician within an approved pathway.

Not sure if this fits your goals?

2-min match →

Side effects

  • Gastrointestinal effects (nausea, vomiting, diarrhoea) during titration
  • Increased heart rate observed in trials
  • Reduced appetite and possible dehydration
  • Long-term safety still being established in Phase 3

Not suitable if

  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Pregnancy or breastfeeding
  • Use outside an approved clinical pathway
Note: Educational information only — not medical advice. Any peptide or GLP-1 use must be under a DHA- or DOH-licensed physician. We do not prescribe, dispense or sell any medication.

Clinics offering this

Every provider below is licensed — a DHA/DOH physician assesses you first, and all therapy is supervised.

No directory clinics list this compound yet — the licensed at-home platforms above cover it.